To keep the conversation going, I posted on Stockhouse:

"We've covered the transferrin receptor approaches as well as the Angiopep-2 approach. What about Armagen's approach using monoclonal antibody against insulin receptor as well as the Canadian National Research Council approach that has highlighted the potential of single domain antibodies against FC5? Mark or JD, care to comment on how xB3 is differentiated from these?"

JD provided a great summary of how xB3 is differentiated from Armagen. Thanks JD!

BearDownAZ